TrialJournal of nanobiotechnology2019

A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients.

Maryam Hafizi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.